There is room for both biological and synthetic products in the market.
Patients/ medical experts already have a choice between the two, and there are many patients where biological products may be more suitable.
Why not have a product portfolio that offer both types of products.
The forecast revenue of ARX is not that far behind PNV for the next few years, proving that there is a market for biological products.
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$1.17 |
Change
-0.055(4.51%) |
Mkt cap ! $815.1M | |||
| Open | High | Low | Value | Volume |
| $1.23 | $1.23 | $1.17 | $2.186M | 1.841M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 14 | 32723 | $1.17 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.17 | 94061 | 51 |
View Market Depth
| Last trade - 14.30pm 07/07/2025 (20 minute delay) ? |
| PNV (ASX) Chart |